Pharmacokinetic variations of tetramethylpyrazine phosphate after oral administration in hepatic precancerous mice and its hepatoprotective effects

References

• XuSteven X, Hui W, An V. Modeling delayed drug effect using discrete-time nonlinear autoregressive models: a connection with indirect response models. J Pharmacokinet Pharmacodyn 2011;38:353–67
   PubMed Web of Science ®Google Scholar
• Matthew DW, Jonathang GH, Iain K. Pharmacokinetic variation. Anaesth Intensive Care Med 2008;9:369–71
   Google Scholar
• Marc Chikhani, Jonathan GH. Pharmacokinetic variation. Anaesth Intensive Care Med 2011;12:368–70
   Google Scholar
• Hirotoshi O, Miki K, Keiichi M, et al. Change of drug excretory pathway by CCl4-induced liver dysfunction in rat. Biochem Pharmacol 2007;74:488–95
   PubMed Web of Science ®Google Scholar
• Wang XB, Wang SS, Zhang QF, et al. Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells. Oncol Rep 2010;23:211–15
   PubMed Web of Science ®Google Scholar
• Zheng CY, Xiao W, Zhu MX, et al. Inhibition of cyclooxygenase-2 by tetramethylpyrazine and its effects on A549 cell invasion and metastasis. Int J Oncol 2012;40:2029–37
   PubMed Web of Science ®Google Scholar
• Chen L, Lu Y, Wu JM, et al. Ligustrazine inhibits B16F10 melanoma metastasis and suppresses angiogenesis induced by Vascular Endothelial Growth Factor. Biochem Biophys Res Commun 2009;386:374–9
   PubMed Web of Science ®Google Scholar
• Yin J, Yu C, Yang Z, et al. Tetramethylpyrazine inhibits migration of SKOV3 human ovarian carcinoma cells and decreases the expression of interleukin-8 via the ERK1/2, p38 and AP-1 signaling pathways. Oncol Rep 2011;26:671–9
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu X, Zuo T, et al. Tetramethylpyrazine reverses multidrug resistance in breast cancer cells through regulating the expression and function of P-glycoprotein. Med Oncol 2012;29:534–38
   PubMed Web of Science ®Google Scholar
• Wang LS, Shi ZF, Zhang YF, et al. Effect of Xiongbing compound on the pharmacokinetics and brain targeting of tetramethylpyrazine. J Pharm Pharmacol 2012;64:1688–94
   PubMed Web of Science ®Google Scholar
• YanYu X, Qineng P, Zhipeng C. A simple gas chromatographic method for the simultaneous determination and pharmacokinetic study of tetramethylpyrazine phosphate and borneol in mouse plasma and brain tissue after oral administration of the fufang tetramethylpyrazine phosphate tablets. J Chromatogr Sci 2008;46:395–400
   PubMed Web of Science ®Google Scholar
• Feng J, Li F, Zhao Y, et al. Brain pharmacokinetics of tetramethylpyrazine after intranasal and intravenous administration in awake rats. Int J Pharm 2009;375:55–60
   PubMed Web of Science ®Google Scholar
• Zhou ZQ, Manguino D, Kewitt K, et al. Spontaneous hepatocellular carcinoma is reduced in transgenic mice overexpressing human O6-methylguanine-DNA methyltransferase. Proc Natl Acad Sci USA 2001;98:12566–71
   PubMed Web of Science ®Google Scholar
• Theumer MG, López AG, Masih DT, et al. Immunobiological effects of AFB1 and AFB1-FB1 mixture in experimental subchronic mycotoxicoses in rats. Toxicology 2003;186:159–70
   PubMed Web of Science ®Google Scholar
• Shirakami Y, Gottesman ME, Blaner WS. Diethylnitrosamine-induced hepatocarcinogenesis is suppressed in lecithin: retinolacyltransferase-deficient mice primarily through retinoid-actions immediately after carcinogen administration. Carcinogenesis 2012;33:268–74
   PubMed Web of Science ®Google Scholar
• Solt DB, Medline A, Farber E. Rapid emergence of carcinogen induced hyperplastic lesion in a new model for the sequential analysis of liver carcinogenesis. Am J Pathol 1977;88:595–618
   PubMed Web of Science ®Google Scholar
• Aleksic K, Lackner C, Geigl JB, et al. Evolution of genomic instability in diethylnitrosamine-induced hepatocarcinogenesis in mice. Hepatology 2011;53:895–904
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang F, Yang L, et al. Ursolic acid inhibits proliferation and induces apoptosis of cancer cells in vitro and in vivo. J Biomed Biotechnol 2011;Article ID 419343:8. doi:10.1155/2011/419343
   Google Scholar
• Kagawa M, Sano T, Ishibashi N, et al. An acyclic retinoid, NIK-333, inhibits N-diethylnitrosamine-induced rat hepatocarcinogenesis through suppression of TGF-alpha expression and cell proliferation. Carcinogenesis 2004;25:979–85
   PubMed Web of Science ®Google Scholar
• Nakatani T, Roy G, Fujimoto N, et al. Sex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemoprevention by leuprorelin. Jpn J Cancer Res 2001;92:249–56
   PubMedGoogle Scholar
• Jain PK, Kharya M, Gajbhiye A. Pharmacological evaluation of mangiferin herbosomes for antioxidant and hepatoprotection potential against ethanol induced hepatic damage. Drug Dev Ind Pharm 2012;Nov 20. doi:10.3109/03639045.2012.738685 [Epub ahead of print]
   Google Scholar
• Lal J, Kumar V, Gupta RC. Pharmacokinetics of oral and transdermal administration of a sulphur mustard decontaminant CC-2 [N,N-dichlorobis(2,4,5-trichlorophenyl) urea] in rats: a preliminary study. Ind J Pharmacol 2003;35:297–303
   Google Scholar
• Lipka E, Lee ID, Langguth P, et al. Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs. J Pharmacokinet Biopharm 1995;23:267–86
   PubMedGoogle Scholar
• Salem FS, Badr MO, Neamat Allah AN. Biochemical and pathological studies on the effects of levamisole and chlorambucil on Ehrlich ascites carcinoma-bearing mice. Vet Ital 2011;47:89–95
   PubMed Web of Science ®Google Scholar
• Shimokawa Y, Okuda K, Kubo Y, et al. Serum glutamic oxalacetic transaminase/glutamic pyruvic transaminase ratios in hepatocellular carcinoma. Cancer 1977;40:319–24
   PubMed Web of Science ®Google Scholar
• Berstine EG, Hooper ML, Grandchamp S, Ephrussi B. Alkaline phosphatase activity in mouse teratoma. Proc Natl Acad Sci USA. 1973;70:3899–903
   PubMed Web of Science ®Google Scholar
• Mulder TP, Court DA, Peters WH. Variability of glutathione S-transferase alpha in human liver and plasma. Clin Chem 1999;45:355–9
   PubMed Web of Science ®Google Scholar
• Huang X, Ren P, Wen AD, et al. Pharmacokinetics of traditional Chinese syndrome and recipe: a hypothesis and its verification (I). World J Gastroenterol 2000;6:384–91
   PubMed Web of Science ®Google Scholar
• Oberle RL, Amidon GL. The Influence of gastric emptying and intestinal transit rates on the plasma level curve of cimetidine: an explanation for the double peak phenomenon. J Pharmacokin Biopharm 1987;15:529–44
   PubMedGoogle Scholar
• Lipka E, Lee ID, Langguth P, et al. Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs. J Pharmacokinet Biopharm 1995;23:267–86
   PubMedGoogle Scholar
• Parquet M, Metman EH, Raizman A, et al. Bioavailability, gastrointestinal transit, solubilization and fecal excretion of ursodeoxy cholic acid in man. Eur J Clin Invest 1985;15:171–8
   PubMed Web of Science ®Google Scholar
• Plusquellec Y, Campistron G, Staveris S, et al. A double-peak phenomenon in the pharmacokinetics of veralipride after oral-administration: a double-site model for drug absorption. J Pharmacokinet Biopharm 1987;15:225–39
   PubMedGoogle Scholar
• Pedersen PV, Miller R. Pharmacokinetics and bioavailability of cimetidine in humans. J Pharm Sci 1980;69:394–8
   PubMed Web of Science ®Google Scholar
• Wang YX, Roy A, Sun L, Lau CE. A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metab Dispos 1999;27:855–9
   PubMed Web of Science ®Google Scholar
• Xian YY, Chen ZP, Ping QN, Chen HX. The enhancing effect of borneol on the absorption of tetramethylpyrazine. Yao Xue Xue Bao 2009;44:915–21
   PubMedGoogle Scholar
• Liu XY, Liu H, Zeng ZW, et al. Pharmacokinetics of ligustrazine ethosome patch in rats and anti-myocardial ischemia and anti-ischemic reperfusion injury effect. Int J Nanomed 2011;6:1391–8
   PubMed Web of Science ®Google Scholar
• Ma L, Fan Y, Wu H, et al. Tissue distribution and targeting evaluation of TMP after oral administration of TMP-loaded microemulsion to mice. Drug Dev Ind Pharm 2012;Oct 4. doi:10.3109/03639045.2012.725733 [Epub ahead of print]
   Google Scholar
• Cai W, Dong SN, Lou YQ. HPLC determination of tetramethylpyrazine in human serum and its pharmacokinetic parameters. Acta Pharm Sinica 1989;12:881–6
   Google Scholar
• Shim HJ, Kim YC, Park KJ, et al. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. J Pharm Sci 2003;92:2185–95
   PubMed Web of Science ®Google Scholar
• McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991;21:42–69
   PubMed Web of Science ®Google Scholar
• Ahn CY, Bae SK, Bae SH, et al. Pharmacokinetics of oltipraz in diabetic rats with liver cirrhosis. Br J Pharmacol 2009;156:1019–28
   PubMed Web of Science ®Google Scholar
• Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008;64:1147–61
   PubMed Web of Science ®Google Scholar
• Sudhamshu KC, Matsutani S, Maruyama H, et al. Doppler study of hepatic vein in cirrhotic patients: correlation with liver dysfunction and hepatic hemodynamics. World J Gastroenterol 2006;12:5853–8
   PubMed Web of Science ®Google Scholar
• Guo SG, Ben CE, Niu JZ, et al. Quantitative study on the distribution and excretion of ∼3H-tetramethyl-pyrazine in mice. Acta Medica Sinica 1989;4:22–5, 80
   Google Scholar
• Verna L, Whysner J, Williams GM. N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther 1996;71:57–81
   PubMed Web of Science ®Google Scholar